

Resource Summary Report

Generated by T1D on Jul 31, 2026

Yoda Project

RRID:SCR_022761

Type: Tool

Proper Citation

Yoda Project (RRID:SCR_022761)

Resource Information

URL: <https://yoda.yale.edu/>

Proper Citation: Yoda Project (RRID:SCR_022761)

Description: Project to promote and facilitate sharing of clinical trial data. Provides set of policies to set standards to enhance data availability and transparency in support of strong scientific research which aims to advance scientific and medical knowledge with goal of improving public health and healthcare delivery. Project has the final decision making rights regarding these policies and granting or denial of data requests, as per contractual agreements between the YODA Project and its partners.

Synonyms: Yale university Open Data Access project, YODA Project, Yale University Open Data Access Project

Resource Type: data or information resource, portal, project portal

Keywords: Data sharing project for clinical trials, clinical trial data, policies, standards to enhance data availability and transparency, granting or denial of data requests

Availability: Free, Freely available

Resource Name: Yoda Project

Resource ID: SCR_022761

Record Creation Time: 20220920T050146+0000

Record Last Update: 20260731T043131+0000

Ratings and Alerts

No rating or validation information has been found for Yoda Project.

No alerts have been found for Yoda Project.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 209 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Tomasini P, et al. (2026) Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 44(1), 54.

Shore N, et al. (2025) Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. *Prostate cancer and prostatic diseases*, 28(3), 828.

Anderson D, et al. (2025) DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 80(3), 602.

Ouerdani A, et al. (2025) Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). *Cancer chemotherapy and pharmacology*, 95(1), 38.

Hungria V, et al. (2025) Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. *Annals of hematology*, 104(5), 2787.

Felip E, et al. (2025) Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA. *Future oncology (London, England)*, 21(12), 1429.

Kim BS, et al. (2025) Determination of Risk Factors Influencing Psoriatic Arthritis Screening and Evaluation Questionnaire Scores in Palmoplantar Pustulosis: Post Hoc Analysis of EPPPIK Study. *Dermatology and therapy*, 15(8), 2233.

Danese S, et al. (2025) Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. *Alimentary pharmacology & therapeutics*, 62(5), 483.

Daneshmand S, et al. (2025) TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 43(33), 3578.

Passaro A, et al. (2025) Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer. *Future oncology (London, England)*, 21(13), 1553.

Fu W, et al. (2025) Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study. *Annals of hematology*, 104(5), 2765.

Malmkvist R, et al. (2025) Axial spondyloarthritis, psoriatic arthritis and systemic lupus erythematosus share common molecular features based on post-hoc analysis of serum biomarkers. *Rheumatology international*, 45(11), 262.

Hieronimus F, et al. (2025) Predicting Remission in Schizophrenia Using Machine Learning-Assessing the Impact of Sample Size and Predictor Overinclusion. *Acta psychiatrica Scandinavica*, 152(6), 441.

Naudet F, et al. (2025) Efficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. *BMC medicine*, 23(1), 677.

Koshino A, et al. (2025) Canagliflozin and iron metabolism in the CREDENCE trial. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 40(4), 696.

Badros A, et al. (2025) Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. *Blood*, 145(3), 300.

Modi ND, et al. (2025) The state of individual participant data sharing for the highest-revenue medicines. *Clinical trials (London, England)*, 22(2), 170.

Tica J, et al. (2025) Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. *Human vaccines & immunotherapeutics*, 21(1), 2450120.

van Bömmel F, et al. (2025) Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B. *Hepatology communications*, 9(3).

Yoshifuji H, et al. (2025) Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis. *Rheumatology advances in practice*, 9(2), rkaf013.